Neuland Labs' revenues for third quarter of FY 2015 decrease 17% to $17.14 million

NewsGuard 100/100 Score

Neuland Laboratories Ltd., (NSE: NEULANDLAB; BSE-Scrip Code:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2015, ended December 31, 2014.

Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs, commented, "Results this quarter reflect a partial interruption in production during the period that resulted from advancing a planned maintenance activity into the quarter. This activity was done to upgrade the facility and augment capacity in order to meet business requirements. The work is now complete and production is back on track. We expect to be operating normally for the remainder of the fiscal year."

Revenues for the third quarter of FY 2015 were $17.14 million (1.09 billion INR), compared to revenues in the third quarter of FY 2014 of $21.27 million (1.31 billion INR), a decrease of 17%.

Neuland reported EBITDA of $2.26 million (143.0 million INR) in the third quarter of FY 2015, compared to EBITDA of $3.12 million (193.23 million INR) in the comparable period in FY 2014, a decrease of 26%.

After-tax profits in the third quarter of FY 2015 were $0.29 million (19.24 million INR), compared to after-tax profits of $1.11 million (68.27 million INR) in the third quarter of FY 2014, a decrease of 72%.

"Our 30-year commitment to outstanding quality and regulatory excellence were recognized in two positive developments during the third quarter," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. "First, we received formal notification that Neuland successfully passed its recent FDA audit. This is our ninth successful FDA audit over the past 18 years, and it extends our positive regulatory record with the most demanding regulatory agencies in the world. Neuland also was awarded a 2015 CMO Leadership Award in the Quality category. This award is especially meaningful since it is based on a survey of our most knowledgeable peers --customers and industry executives."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
LungVax vaccine uses DNA technology to prevent lung cancer